As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Content to be used in accordance with local CPO guidelines
Symptomatic Skeletal Events, Health-related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-naive Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer: Third Interim Analysis of PSMAfore
Karim Fizazi*, Michael J. Morris, Neal D. Shore, Kim N. Chi, Michael Crosby, Johann S. de Bono, Ken Herrmann, Guilhem Roubaud, James Nagarajah, Mark Fleming, Brian Lewis, Luke Nordquist, Daniel Castellano, Natalie Carnahan, Samson Ghebremariam, Marianna Hertelendi, Oliver Sartor
Presentation #1599P – Poster
Hall 6 | Sunday, September 15, 2024 | 09:00-17:00 CEST
Haematologic Impact of [177Lu]Lu-PSMA-617 versus ARPI Change in Patients with Metastatic Castration-resistant Prostate Cancer in PSMAfore
Kim N. Chi*, Oliver Sartor, Karim Fizazi, Johann S. de Bono, Neal D. Shore, Ken Herrmann, Daniel Castellano, Josep M. Piulats, Aude Fléchon, Xiao X. Wei, Hyun Kim, Michael T. Schweizer, Shaheen Alanee, Samson Ghebremariam, Marianna Hertelendi, Michael J. Morris
Presentation #1611P – Poster
Hall 6 | Sunday, September 15, 2024 | 09:00-17:00 CEST
Factors Influencing Clinical and Biological Response in Patients Treated with [177Lu]Lu-PSMA-617 under France’s Early Access Program.
Vincent Habouzit
Presentation #1628P – Poster
Hall 6 | Sunday, September 15, 2024 | 09:00-17:00 CEST
Characteristics, tolerance, and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
David Tonnelet
Presentation #1651P – Poster
Hall 6 | Sunday, September 15, 2024 | 09:00-17:00 CEST
